|
US6080216A
(en)
*
|
1998-04-22 |
2000-06-27 |
3M Innovative Properties Company |
Layered alumina-based abrasive grit, abrasive products, and methods
|
|
EP1688420A4
(en)
*
|
2003-11-19 |
2008-10-22 |
Japan Tobacco Inc |
5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
|
|
US20070049593A1
(en)
*
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
|
US7795247B2
(en)
*
|
2004-10-26 |
2010-09-14 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
|
AU2005298412B2
(en)
*
|
2004-10-26 |
2011-06-09 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
|
JP4705164B2
(ja)
|
2005-05-02 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Hcvns3プロテアーゼ阻害剤
|
|
WO2009032123A2
(en)
*
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
Tetracyclic indole derivatives and their use for treating or preventing viral infections
|
|
WO2007016441A1
(en)
|
2005-08-01 |
2007-02-08 |
Merck & Co., Inc. |
Macrocyclic peptides as hcv ns3 protease inhibitors
|
|
GB0518390D0
(en)
*
|
2005-09-09 |
2005-10-19 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US7399758B2
(en)
*
|
2005-09-12 |
2008-07-15 |
Meanwell Nicholas A |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7473688B2
(en)
|
2005-09-13 |
2009-01-06 |
Bristol-Myers Squibb Company |
Indolobenzazepine HCV NS5B inhibitors
|
|
WO2007092000A1
(en)
*
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
|
US7456165B2
(en)
|
2006-02-08 |
2008-11-25 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
|
GB0608928D0
(en)
*
|
2006-05-08 |
2006-06-14 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
US7456166B2
(en)
*
|
2006-05-17 |
2008-11-25 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7521443B2
(en)
*
|
2006-05-17 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
CN101443336B
(zh)
*
|
2006-05-17 |
2012-07-04 |
百时美施贵宝公司 |
环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
|
|
US7521441B2
(en)
*
|
2006-05-22 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7521442B2
(en)
|
2006-05-25 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
CN101490054B
(zh)
*
|
2006-05-25 |
2012-05-16 |
百时美施贵宝公司 |
环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
|
|
US7452876B2
(en)
*
|
2006-06-08 |
2008-11-18 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
US7906619B2
(en)
|
2006-07-13 |
2011-03-15 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
|
AR062827A1
(es)
*
|
2006-07-20 |
2008-12-10 |
Genelabs Tech Inc |
Inhibidores virales policiclicos, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de una infeccion viral mediada porl el virus de la hepatitis c
|
|
CA2667146C
(en)
|
2006-10-24 |
2016-01-19 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
US8377873B2
(en)
|
2006-10-24 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
JP5345941B2
(ja)
|
2006-10-24 |
2013-11-20 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvns3プロテアーゼ阻害剤
|
|
KR101615500B1
(ko)
|
2006-10-27 |
2016-04-27 |
머크 샤프 앤드 돔 코포레이션 |
Hcv ns3 프로테아제 억제제
|
|
US8377874B2
(en)
|
2006-10-27 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
JP2010513450A
(ja)
*
|
2006-12-20 |
2010-04-30 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
抗ウイルス性インドール
|
|
CN101611002A
(zh)
|
2006-12-22 |
2009-12-23 |
先灵公司 |
用于治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
|
|
ATE543808T1
(de)
|
2006-12-22 |
2012-02-15 |
Schering Corp |
5,6-ring-annelierte indolderivate und ihre verwendung
|
|
CN101631773A
(zh)
*
|
2006-12-22 |
2010-01-20 |
先灵公司 |
治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
|
|
US7541351B2
(en)
*
|
2007-01-11 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7541352B2
(en)
*
|
2007-02-02 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7517872B2
(en)
|
2007-02-22 |
2009-04-14 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
CA2679377A1
(en)
*
|
2007-02-26 |
2008-09-04 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of hcv replication
|
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
|
US7998951B2
(en)
*
|
2007-03-05 |
2011-08-16 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
|
CN101679437B
(zh)
*
|
2007-03-13 |
2013-04-17 |
百时美施贵宝公司 |
环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
|
|
US7547690B2
(en)
*
|
2007-03-14 |
2009-06-16 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US7538102B2
(en)
|
2007-03-14 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US7521444B2
(en)
*
|
2007-03-14 |
2009-04-21 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7541353B2
(en)
|
2007-03-14 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7538103B2
(en)
|
2007-03-15 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
MX2009011930A
(es)
|
2007-05-04 |
2009-11-18 |
Vertex Pharma |
Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
|
|
AU2008277440A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
|
JP5433573B2
(ja)
|
2007-07-19 |
2014-03-05 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
抗ウイルス剤としての大環状化合物
|
|
US7652004B2
(en)
*
|
2007-08-09 |
2010-01-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8143243B2
(en)
*
|
2007-08-09 |
2012-03-27 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7642251B2
(en)
*
|
2007-08-09 |
2010-01-05 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
KR20100049667A
(ko)
|
2007-08-29 |
2010-05-12 |
쉐링 코포레이션 |
바이러스 감염 치료용 2,3-치환된 인돌 유도체
|
|
AU2008295485B2
(en)
|
2007-08-29 |
2013-09-05 |
Merck Sharp & Dohme Corp. |
2,3-substituted azaindole derivatives for treating viral infections
|
|
TW200924780A
(en)
|
2007-08-29 |
2009-06-16 |
Schering Corp |
2-carboxy substituted indole derivatives and methods of use thereof
|
|
CA2705586A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
WO2009064852A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
US8124601B2
(en)
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US8129367B2
(en)
*
|
2007-11-21 |
2012-03-06 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
WO2009076747A1
(en)
|
2007-12-19 |
2009-06-25 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
|
ES2389994T3
(es)
|
2007-12-24 |
2012-11-05 |
Janssen R&D Ireland |
Indoles macrocíclicos como inhibidores del virus de la hepatitis C
|
|
US8147818B2
(en)
*
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
AU2009228451A1
(en)
*
|
2008-03-27 |
2009-10-01 |
Bristol-Myers Squibb Company |
Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors
|
|
MX2010010245A
(es)
*
|
2008-03-27 |
2010-10-05 |
Bristol Myers Squibb Co |
Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
|
|
KR20100139082A
(ko)
*
|
2008-03-27 |
2010-12-31 |
브리스톨-마이어스 스큅 컴퍼니 |
C형 간염 치료를 위한 화합물
|
|
CN102046630A
(zh)
*
|
2008-03-27 |
2011-05-04 |
百时美施贵宝公司 |
吡咯烷稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
|
|
AU2009241445A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
US8133884B2
(en)
*
|
2008-05-06 |
2012-03-13 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
MX2010013630A
(es)
|
2008-06-13 |
2010-12-21 |
Schering Corp |
Derivados triciclicos de indol y metodos de uso de los mismos.
|
|
TWI454476B
(zh)
|
2008-07-08 |
2014-10-01 |
Tibotec Pharm Ltd |
用作c型肝炎病毒抑制劑之巨環吲哚衍生物
|
|
PT2310095E
(pt)
|
2008-07-22 |
2012-11-16 |
Angeletti P Ist Richerche Bio |
Compostos de quinoxalina macrocílicos como inibidores da protease ns3 do hcv
|
|
CN102203095A
(zh)
|
2008-08-11 |
2011-09-28 |
葛兰素史密丝克莱恩有限责任公司 |
用于治疗变应性疾病、炎性疾病和感染性疾病的嘌呤衍生物
|
|
CN102176911B
(zh)
|
2008-08-11 |
2014-12-10 |
葛兰素史密丝克莱恩有限责任公司 |
新的腺嘌呤衍生物
|
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
|
NZ592668A
(en)
*
|
2008-12-10 |
2013-12-20 |
Achillion Pharmaceuticals Inc |
New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
|
NZ592705A
(en)
*
|
2008-12-10 |
2013-02-22 |
Achillion Pharmaceuticals Inc |
4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
|
|
WO2010072598A1
(en)
*
|
2008-12-22 |
2010-07-01 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compounds
|
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
|
SG172363A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
|
JP2012514605A
(ja)
|
2009-01-07 |
2012-06-28 |
サイネクシス,インコーポレーテッド |
Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体
|
|
EP2396329B1
(en)
*
|
2009-02-11 |
2014-10-29 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis c
|
|
US8143244B2
(en)
*
|
2009-02-26 |
2012-03-27 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US20190127365A1
(en)
|
2017-11-01 |
2019-05-02 |
Merck Sharp & Dohme Corp. |
Inhibitors of hepatitis c virus replication
|
|
NZ595410A
(en)
|
2009-03-27 |
2013-12-20 |
Merck Sharp & Dohme |
Inhibitors of hepatitis c virus replication
|
|
CA2756870A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-pyridinone compounds
|
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
|
US8575340B2
(en)
|
2010-02-10 |
2013-11-05 |
Glaxosmithkline Llc |
Purine derivatives and their pharmaceutical uses
|
|
SI2534149T1
(sl)
|
2010-02-10 |
2015-02-27 |
Glaxosmithkline Llc Corporation Service Company |
6-amino-2-((1S)-1-metilbutil)oksi)-9-(5-(1-pipridinil)pentil)-7,9- dihidro-8H purin-8-on maleat
|
|
KR20130008040A
(ko)
*
|
2010-03-09 |
2013-01-21 |
머크 샤프 앤드 돔 코포레이션 |
융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법
|
|
WO2011123668A2
(en)
|
2010-03-31 |
2011-10-06 |
Pharmasset, Inc. |
Stereoselective synthesis of phosphorus containing actives
|
|
TW201136945A
(en)
|
2010-03-31 |
2011-11-01 |
Pharmasset Inc |
Purine nucleoside phosphoramidate
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
EP2585438B1
(en)
|
2010-06-24 |
2014-08-20 |
Janssen R&D Ireland |
PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
|
|
JP2013540122A
(ja)
*
|
2010-09-29 |
2013-10-31 |
メルク・シャープ・エンド・ドーム・コーポレイション |
縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
|
|
EP2646453A1
(en)
|
2010-11-30 |
2013-10-09 |
Gilead Pharmasset LLC |
Compounds
|
|
US8937041B2
(en)
|
2010-12-30 |
2015-01-20 |
Abbvie, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
|
US8951964B2
(en)
|
2010-12-30 |
2015-02-10 |
Abbvie Inc. |
Phenanthridine macrocyclic hepatitis C serine protease inhibitors
|
|
WO2012122716A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
|
SG10201602044WA
(en)
|
2011-09-16 |
2016-04-28 |
Gilead Pharmassett Llc |
Methods For Treating HCV
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
DE112012003457T5
(de)
|
2011-10-21 |
2015-03-12 |
Abbvie Inc. |
Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
TWI532487B
(zh)
|
2011-10-21 |
2016-05-11 |
艾伯維有限公司 |
治療c型肝炎病毒(hcv)之方法
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
MY175254A
(en)
|
2012-04-26 |
2020-06-17 |
G1 Therapeutics Inc |
Synthesis of lactams
|
|
CA2879398A1
(en)
*
|
2012-07-18 |
2014-01-23 |
Bristol-Myers Squibb Holdings Ireland |
Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
|
|
WO2014110687A1
(en)
|
2013-01-16 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
|
|
AU2014202687A1
(en)
|
2013-01-31 |
2014-08-14 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121416A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
AU2014227849A1
(en)
|
2013-03-15 |
2015-10-01 |
Achillion Pharmaceuticals, Inc. |
Sovaprevir polymorphs and methods of manufacture thereof
|
|
WO2014145600A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
|
|
WO2014145507A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
|
SI3038601T1
(sl)
|
2013-08-27 |
2020-07-31 |
Gilead Pharmasset Llc |
Formulacija kombinacije dveh protivirusnih spojin
|
|
WO2015061407A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
|
EP3089757A1
(en)
|
2014-01-03 |
2016-11-09 |
AbbVie Inc. |
Solid antiviral dosage forms
|
|
WO2015124591A1
(en)
|
2014-02-20 |
2015-08-27 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
|
|
BR112017009648A2
(pt)
|
2014-11-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
|
|
KR101949108B1
(ko)
|
2015-12-03 |
2019-02-15 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드
|
|
CN109563081A
(zh)
|
2016-04-07 |
2019-04-02 |
葛兰素史克知识产权开发有限公司 |
可用作蛋白调节剂的杂环酰胺类
|
|
PE20181884A1
(es)
|
2016-04-07 |
2018-12-07 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas utiles como moduladores de proteinas
|
|
CN109689063A
(zh)
|
2016-04-28 |
2019-04-26 |
埃默里大学 |
含有炔烃的核苷酸和核苷治疗组合物及其相关用途
|
|
KR20200035234A
(ko)
|
2017-05-12 |
2020-04-02 |
마발론 테라퓨틱스 리미티드 |
그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 헤테로사이클릭 화합물
|
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
|
TW201927771A
(zh)
|
2017-10-05 |
2019-07-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
可作為蛋白質調節劑之雜環醯胺及其使用方法
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
US20220251079A1
(en)
|
2019-05-16 |
2022-08-11 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US12415785B2
(en)
|
2019-12-18 |
2025-09-16 |
Ctxt Pty Ltd |
Compound modulators of sting
|
|
US12274700B1
(en)
|
2020-10-30 |
2025-04-15 |
Accencio LLC |
Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
|